Cefdinir[ (Omnicef) ] Drug Information

Contains Cefdinir drug information and provides Cefdinir drug indication, contraindication, special concerns, side effects, overdose management and dosage
Search Drugs by Generic or Trade Name:
Browse Drugs by Generic Name:
[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z ]

List of Contents:
  • Indications
  • Contraindications
  • Special Concerns
  • Side Effects
  • Overdose Management
  • Dosage

  • Indications:
    Adults: (1) Community-acquired pneumonia or acute exacerbations of chronic bronchitis due to Haemophilus influenzae (including ?-lactamase producing strains), Haemophilus parainfluenzae (including ?-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including ?-lactamase producing strains). (2) Acute maxillary sinusitis due to Haemophilus influenzae (including ?-lactamase producing strains), Streptococcius pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including ?-lactamase producing strains). (3) Uncomplicated skin and skin structure infections due to Staphylococcus aureus (including ?-lactamase producing strains and Streptococcus pyogenes.)

    Children (6 months through 12 years): (1) Acute bacterial otitis media due to H. influenzae (including ?-lactamase producing strains), S. pneumoniae (penicillin-susceptible strains only), and M. catarrhalis (including ?-lactamase producing strains). (2) Pharyngitis/tonsillitis due to S. pyogenes. Acute maxillary sinusitis. (3) Uncomplicated skin and skin structure infections due to S. aureus (including ?-lactamase producing strains) and S. pyogenes.



    Note: The suspension is approved for use for all infections in children indicated above.
    Back to Top
    Contraindications:
    Allergy to cephalosporins.
    Back to Top
    Special Concerns:
    Reduce dose in compromised renal function. Safety and efficacy have not been determined in infants less than 6 months of age.
    Back to Top
    Side Effects:
    No Available information
    Back to Top
    Overdose Management:
    No Available information
    Back to Top
    Drug Interactions:
    Antacids, aluminum- or magnesium-containing / Absorption of cefdinir Probenecid / Plasma levels of cefdinir enhanced effect
    Back to Top
    Dosage:
    Capsules Community-acquired pneumonia, uncomplicated skin and skin structure infections.

    Adults and adolescents age 13 and older: 300 mg q 12 hr for 10 days.

    Acute exacerbations of chronic bronchitis, acute maxillary sinusitis, or pharyngitis/tonsillitis.

    Adults and adolescents age 13 and older: 300 mg q 12 hr or 600 mg q 24 hr for 10 days (5-10 days for pharyngitis/tonsillitis). Alternatively, 300 mg b.i.d. for 5 days for acute exacerbations of chronic bronchitis.

    Oral Suspension Acute bacterial otitis media, acute maxillary sinusitis, pharyngitis/tonsillitis.

    Children, 6 months through 12 years: 7 mg/kg q 12 hr or 14 mg/kg q 24 hr for 10 days (5 days for acute otitis media and 5-10 days for pharyngitis/tonsillitis).

    Uncomplicated skin and skin structure infections.

    Children, 6 months through 12 years: 7 mg/kg q 12 hr for 10 days.
    Back to Top